GreenBone Ortho announced that it received CE Mark approval for its bone substitute product that could serve as an alternative to traditional bone grafts.
The Faenza, Italy–based company’s bone substitute is designed to limit the surgical and postoperative complications related to bone defects that are either created surgically or have resulted from traumatic injuries to bones, extremities and the pelvis.
GreenBone’s substitute differs from the traditional autologous, allograft and synthetic forms of bone grafts. According to the company, the bone substitute is a synthetic, acellular, biomimetic product constructed from the biomorphic transformation of rattan wood — touted as the first of its kind. It is designed to restore mobility, reduce pain and improve quality of life in a safe, efficacious and cost-effective manner.
In a news release CEO Lorenzo Pradella labeled the regulatory approval as a “milestone for GreenBone” as the company is set to market its product in Europe.